IP Library Granted Patent US 8,188,146
Granted Patent B2
US 8,188,146 · App. 12/052,598 · Granted May 29, 2012

Highly purified ethyl EPA and other EPA derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,188,146
App. No.
12/052,598
Granted
May 29, 2012
Kind
B2
Abstract

A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided.

Claims (10)

1. A pharmaceutical composition comprising one or more fatty acids, at least 95% of which are in the form of ethyl-eicosapentaenoic acid, wherein the composition contains no docosahexaenoic acid and the composition is present in a capsule.

2. The composition of claim 1 wherein the composition contains less than 3% of any fatty acid other than eicosapentaenoic acid.

3. The composition of claim 2 wherein the capsule is a gelatin capsule.

4. The composition of any one of claim 1 , 2 , or 3 wherein the ethyl-eicosapentaenoic acid is present in the composition in an amount of 250 mg to 1000 mg.

5. A pharmaceutical composition comprising 250 mg to 1000 mg of fatty acids at least 95% of which are in the form of ethyl eicosapentaenoic acid, wherein the composition contains no docosahexaenoic acid, and the composition is present in a capsule.

6. A pharmaceutical composition comprising 250 mg to 1000 mg of fatty acids at least 95% of which are in the form of ethyl-eicosapentaenoic acid, wherein the composition contains (a) less than 5% in aggregate of arachidonic acid and n-3 docosapentaenoic acid, and (b) no docosahexaenoic acid; and wherein the composition is present in a capsule.

7. The pharmaceutical composition of claim 5 wherein the composition contains arachidonic acid in an amount less than 3%, by weight, of said fatty acids.

8. The pharmaceutical composition of claim 6 wherein the composition contains docosapentaenoic acid in an amount less than 3%, by weight, of said fatty acids.

9. The pharmaceutical composition of claim 6 wherein the composition contains arachidonic acid and docosapentaenoic acid in an aggregate amount of less than 3%, by weight, of said fatty acids.

10. The pharmaceutical composition of claim 6 wherein the capsule comprises about 1000 mg of said composition.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Nov 19, 2020
From: CPPIB CREDIT EUROPE S.À R.L.
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 054484/0552 →
SECURITY INTEREST Recorded Dec 21, 2017
From: AMARIN PHARMACEUTICALS IRELAND LIMITED
To: CPPIB CREDIT EUROPE S.À R.L.
Reel/Frame 044938/0257 →
PATENT SECURITY ASSIGNMENT AND ASSUMPTION AGREEMENT Recorded Dec 20, 2017
From: BIOPHARMA SECURED DEBT FUND II HOLDINGS CAYMAN LP
To: CPPIB CREDIT EUROPE S.À R.L.
Reel/Frame 044956/0395 →
SECURITY AGREEMENT Recorded Dec 19, 2012
From: AMARIN PHARMACEUTICALS IRELAND LIMITED
To: BIOPHARMA SECURED DEBT FUND II HOLDINGS CAYMAN LP
Reel/Frame 029499/0087 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 31, 2012
From: AMARIN CORPORATION PLC
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 028295/0289 →
PROOF OF OWNERSHIP OF SHARES Recorded Oct 9, 2008
From: AMARIN NEUROSCIENCE LIMITED
To: AMARIN CORPORATION PLC.
Reel/Frame 021654/0657 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2008
From: PEET, MALCOLM; VADDADI, KRISHNA S.
To: LAXDALE LIMITED
Reel/Frame 021539/0624 →
CHANGE OF NAME Recorded Sep 16, 2008
From: LAXDALE LIMITED
To: AMARIN NEUROSCIENCE LIMITED
Reel/Frame 021537/0909 →